Literature DB >> 19156393

[Community-acquired pneumonia].

T Welte1.   

Abstract

Community-acquired pneumonia is the most common cause of death amongst all infectious diseases in the world. Mortality is low in patients treated as outpatients (<1%), but significantly raised (close to 14% in Germany) in hospital admitted patients. Especially at risk are patients from nursing homes, and patients with co-morbidities (chronic heart failure, chronic liver disease, neurological disease). Appropriate initial antibiotic therapy is the key factor in influencing patient outcome. Today, a risk stratification approach is used for initiating antibiotic therapy. Low risk patients can be treated as outpatients with a narrow spectrum beta-lactam for 5 days. With an increasing number of risk factors hospital admittance is recommended and broader spectrum antibiotics providing additional cover for atypical pathogens are required. Influenza and pneumococcal vaccination are proven to reduce the number and the severity of CAP cases significantly. The recommendations of the Ständige Impfkommission (Stiko) in Germany therefore warrant implementation in daily practice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19156393     DOI: 10.1007/s00108-008-2294-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  29 in total

1.  Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.

Authors:  Mirjam Christ-Crain; Daiana Stolz; Roland Bingisser; Christian Müller; David Miedinger; Peter R Huber; Werner Zimmerli; Stephan Harbarth; Michael Tamm; Beat Müller
Journal:  Am J Respir Crit Care Med       Date:  2006-04-07       Impact factor: 21.405

2.  Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study.

Authors:  M M van der Eerden; F Vlaspolder; C S de Graaff; T Groot; W Bronsveld; H M Jansen; W G Boersma
Journal:  Thorax       Date:  2005-08       Impact factor: 9.139

3.  Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia.

Authors:  J D Chalmers; A Singanayagam; A T Hill
Journal:  Thorax       Date:  2008-05-20       Impact factor: 9.139

4.  Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.

Authors:  Andrés de Roux; B Schmöle-Thoma; B Schmöele-Thoma; G R Siber; J G Hackell; A Kuhnke; N Ahlers; S A Baker; A Razmpour; E A Emini; P D Fernsten; W C Gruber; S Lockhart; O Burkhardt; T Welte; H M Lode
Journal:  Clin Infect Dis       Date:  2008-04-01       Impact factor: 9.079

5.  Viral community-acquired pneumonia in nonimmunocompromised adults.

Authors:  Andrés de Roux; Maria A Marcos; Elisa Garcia; Jose Mensa; Santiago Ewig; Hartmut Lode; Antoni Torres
Journal:  Chest       Date:  2004-04       Impact factor: 9.410

6.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

7.  An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome.

Authors:  Victor L Yu; Christine C C Chiou; Charles Feldman; Ake Ortqvist; Jordi Rello; Arthur J Morris; Larry M Baddour; Carlos M Luna; David R Snydman; Margaret Ip; Wen Chien Ko; M Bernadete F Chedid; Antoine Andremont; Keith P Klugman
Journal:  Clin Infect Dis       Date:  2003-07-07       Impact factor: 9.079

8.  Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.

Authors:  Antoni Torres; Javier Garau; Pierre Arvis; Jean Carlet; Shurjeel Choudhri; Amar Kureishi; Marie-Aude Le Berre; Hartmut Lode; John Winter; Robert C Read
Journal:  Clin Infect Dis       Date:  2008-05-15       Impact factor: 9.079

9.  Quinolone resistance among pneumococci: therapeutic and diagnostic implications.

Authors:  Donald E Low
Journal:  Clin Infect Dis       Date:  2004-05-15       Impact factor: 9.079

10.  High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.

Authors:  Lala M Dunbar; Richard G Wunderink; Michael P Habib; Leon G Smith; Alan M Tennenberg; Mohammed M Khashab; Barbara A Wiesinger; Jim X Xiang; Neringa Zadeikis; James B Kahn
Journal:  Clin Infect Dis       Date:  2003-08-28       Impact factor: 9.079

View more
  3 in total

1.  [Pneumonia].

Authors:  C Herold; H Prosch
Journal:  Radiologe       Date:  2017-01       Impact factor: 0.635

2.  Ampicillin/sulbactam in elderly patients with community-acquired pneumonia.

Authors:  J Majcher-Peszynska; M Loebermann; S Klammt; S Frimmel; R G Mundkowski; T Welte; E C Reisinger; B Drewelow
Journal:  Infection       Date:  2013-08-01       Impact factor: 3.553

Review 3.  [Antibiotic treatment of nosocomial pneumonia].

Authors:  S Weiterer; D Störzinger; M Bernhard; K Mayer; C Lass-Flörl; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2011-03       Impact factor: 1.041

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.